Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1991 Dec;54(12):1055–1060. doi: 10.1136/jnnp.54.12.1055

Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study.

W H Likosky 1, B Fireman 1, R Elmore 1, G Eno 1, K Gale 1, G B Goode 1, K Ikeda 1, J Laster 1, C Mosher 1, J Rozance 1, et al.
PMCID: PMC1014677  PMID: 1783915

Abstract

The value of a short course of intensive immunosuppression with cyclophosphamide in stabilising chronic progressive multiple sclerosis (MS) was examined in a randomised single-blinded, placebo-controlled clinical trial. Forty two patients, from the Kaiser Permanente Medical Care Program, Northern California, were studied. Twenty two patients received a short course of cyclophosphamide in an outpatient neurology clinic until their leucocyte counts fell below 4000/mm3, and 20 patients received folic acid. Level of disability, impairment of functional systems, and performance of social roles were assessed before randomisation and reassessed 12, 18, and 24 months after therapy. In both the cyclophosphamide and folic acid groups, the mean level of disability increased from the baseline examination to the 12 month follow up examination (the primary endpoint) by 0.5 on Kurtzke's Expanded Disability Status Scale, indicating similar disease progression in the two groups. Although immunosuppression therapy can be safely administered to MS patients in an outpatient clinic, evidence of substantial benefits was not found.

Full text

PDF
1055

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams C. W. Pathology of multiple sclerosis: progression of the lesion. Br Med Bull. 1977 Jan;33(1):15–20. doi: 10.1093/oxfordjournals.bmb.a071388. [DOI] [PubMed] [Google Scholar]
  2. Aimard G., Girard P. F., Raveau J. Sclérose en plaques et processus d'auto-immunisation. Traitement par les anti-mitotiques. Lyon Med. 1966 Feb 6;215(6):345–352. [PubMed] [Google Scholar]
  3. Carter J. L., Hafler D. A., Dawson D. M., Orav J., Weiner H. L. Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients. Neurology. 1988 Jul;38(7 Suppl 2):9–14. [PubMed] [Google Scholar]
  4. Confavreux C., Aimard G., Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain. 1980 Jun;103(2):281–300. doi: 10.1093/brain/103.2.281. [DOI] [PubMed] [Google Scholar]
  5. Drachman D. A., Paterson P. Y., Schmidt R. T., Spehlmann R. F. Cyclophosphamide in exacerbations of multiple sclerosis. Therapeutic trial and a strategy for pilot drug studies. J Neurol Neurosurg Psychiatry. 1975 Jun;38(6):592–597. doi: 10.1136/jnnp.38.6.592. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Girard P. F., Aimard G., Pellet H. Thérapeutique immuno-dépressive en neurologie. Presse Med. 1967 Apr 22;75(19):967–968. [PubMed] [Google Scholar]
  7. Gonsette R. E., Demonty L., Delmotte P. Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years. J Neurol. 1977 Feb 17;214(3):173–181. doi: 10.1007/BF00316148. [DOI] [PubMed] [Google Scholar]
  8. Hauser S. L., Dawson D. M., Lehrich J. R., Beal M. F., Kevy S. V., Propper R. D., Mills J. A., Weiner H. L. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med. 1983 Jan 27;308(4):173–180. doi: 10.1056/NEJM198301273080401. [DOI] [PubMed] [Google Scholar]
  9. Hommers O. R., Lamers K. J., Reekers P. Effect of intensive immunosuppression on the course of chronic progressive multiple sclerosis. J Neurol. 1980;223(3):177–190. doi: 10.1007/BF00313182. [DOI] [PubMed] [Google Scholar]
  10. Kurtzke J. F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11):1444–1452. doi: 10.1212/wnl.33.11.1444. [DOI] [PubMed] [Google Scholar]
  11. Lisak R. P. Overview of the rationale for immunomodulating therapies in multiple sclerosis. Neurology. 1988 Jul;38(7 Suppl 2):5–8. [PubMed] [Google Scholar]
  12. McFarlin D. E., McFarland H. F. Multiple sclerosis (second of two parts). N Engl J Med. 1982 Nov 11;307(20):1246–1251. doi: 10.1056/NEJM198211113072005. [DOI] [PubMed] [Google Scholar]
  13. Mickey M. R., Ellison G. W., Fahey J. L., Moody D. J., Myers L. W. Correlation of clinical and immunologic states in multiple sclerosis. Arch Neurol. 1987 Apr;44(4):371–375. doi: 10.1001/archneur.1987.00520160013006. [DOI] [PubMed] [Google Scholar]
  14. Millac P., Miller H. Cyclophosphamide in multiple sclerosis. Lancet. 1969 Apr 12;1(7598):783–783. doi: 10.1016/s0140-6736(69)91788-7. [DOI] [PubMed] [Google Scholar]
  15. Myers L. W., Fahey J. L., Moody D. J., Mickey M. R., Frane M. V., Ellison G. W. Cyclophosphamide 'pulses' in chronic progressive multiple sclerosis. A preliminary clinical trial. Arch Neurol. 1987 Aug;44(8):828–832. doi: 10.1001/archneur.1987.00520200032014. [DOI] [PubMed] [Google Scholar]
  16. Puri H. C., Campbell R. A. Cyclophosphamide and malignancy. Lancet. 1977 Jun 18;1(8025):1306–1306. doi: 10.1016/s0140-6736(77)91336-8. [DOI] [PubMed] [Google Scholar]
  17. Rinne U. K., Sonninen V., Tuovinen T. Corticotrophin treatment in multiple sclerosis. Acta Neurol Scand. 1968;44(2):207–218. doi: 10.1111/j.1600-0404.1968.tb05567.x. [DOI] [PubMed] [Google Scholar]
  18. Schilsky R. L., Lewis B. J., Sherins R. J., Young R. C. Gonadal dysfunction in patients receiving chemotherapy for cancer. Ann Intern Med. 1980 Jul;93(1):109–114. doi: 10.7326/0003-4819-93-1-109. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES